» Articles » PMID: 39316257

Therapeutic Role of Probiotics Against Environmental-Induced Hepatotoxicity: Mechanisms, Clinical Perspectives, Limitations, and Future

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatotoxicity is one of the biggest health challenges, particularly in the context of liver diseases, often aggravated by gut microbiota dysbiosis. The gut-liver axis has been regarded as a key idea in liver health. It indicates that changes in gut flora caused by various hepatotoxicants, including alcoholism, acetaminophen, carbon tetrachloride, and thioacetamide, can affect the balance of the gut's microflora, which may lead to increased dysbiosis and intestinal permeability. As a result, bacterial endotoxins would eventually enter the bloodstream and liver, causing hepatotoxicity and inducing inflammatory reactions. Many treatments, including liver transplantation and modern drugs, can be used to address these issues. However, because of the many side effects of these approaches, scientists and medical experts are still hoping for a therapeutic approach with fewer side effects and more positive results. Thus, probiotics have become well-known as an adjunctive strategy for managing, preventing, or reducing hepatotoxicity in treating liver injury. By altering the gut microbiota, probiotics offer a secure, non-invasive, and economical way to improve liver health in the treatment of hepatotoxicity. Through various mechanisms such as regulation of gut microbiota, reduction of pathogenic overgrowth, suppression of inflammatory mediators, modification of hepatic lipid metabolism, improvement in the performance of the epithelial barrier of the gut, antioxidative effects, and modulation of mucosal immunity, probiotics play their role in the treatment and prevention of hepatotoxicity. This review highlights the mechanistic effects of probiotics in environmental toxicants-induced hepatotoxicity and current findings on this therapeutic approach's experimental and clinical trials.

References
1.
Rusyn I, Arzuaga X, Cattley R, Corton J, Ferguson S, Godoy P . Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity. Hepatology. 2021; 74(6):3486-3496. PMC: 8901129. DOI: 10.1002/hep.31999. View

2.
Martinez-Sena T, Moro E, Moreno-Torres M, Quintas G, Hengstler J, Castell J . Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved. Arch Toxicol. 2023; 97(6):1723-1738. PMC: 10182947. DOI: 10.1007/s00204-023-03474-8. View

3.
Paik J, Golabi P, Younossi Y, Mishra A, Younossi Z . Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020; 72(5):1605-1616. DOI: 10.1002/hep.31173. View

4.
Asrani S, Devarbhavi H, Eaton J, Kamath P . Burden of liver diseases in the world. J Hepatol. 2018; 70(1):151-171. DOI: 10.1016/j.jhep.2018.09.014. View

5.
Wahlang B, Jin J, Beier J, Hardesty J, Daly E, Schnegelberger R . Mechanisms of Environmental Contributions to Fatty Liver Disease. Curr Environ Health Rep. 2019; 6(3):80-94. PMC: 6698418. DOI: 10.1007/s40572-019-00232-w. View